U.S. pharma giant copyright scrapped two experimental weight loss products last year—a the moment-day by day capsule, lotiglipron, on account of elevated liver enzymes as well as a two times-every day capsule, danuglipron, resulting from potent Unintended effects—but CEO Albert Bourl